• ELO, Oxford & AstraZeneca COVID-19 Vaccine: How to Execute? (Part IV)

    How to Execute? (Part IV) This series of four blog posts focus on the entrepreneurial story of how the University of Oxford invented a COVID-19 vaccine and entered into a partnership with AstraZeneca to distribute 3 billion doses globally. This year’s ELO Oxford Entrepreneurial Leaders Programme will include a case study of the development and roll-out of the Oxford AstraZeneca Vaccine and the lessons on innovation and entrepreneurship to be learned for global business leaders. The ELO Oxford cohort will get first-hand insights into how to go from idea to opportunity to then impacting the world. This is one of the most important stories of the COVID pandemic. We will be at the epicentre of this success story. read more
  • ELO, Oxford & AstraZeneca COVID-19 Vaccine: What's The Deal? (Part III)

    What's The Deal? (Part III) This series of four blog posts focus on the entrepreneurial story of how the University of Oxford invented a COVID-19 vaccine and entered into a partnership with AstraZeneca to distribute 3 billion doses globally. This year’s ELO Oxford Entrepreneurial Leaders Programme will include a case study of the development and roll-out of the Oxford AstraZeneca Vaccine and the lessons on innovation and entrepreneurship to be learned for global business leaders. The ELO Oxford cohort will get first-hand insights into how to go from idea to opportunity to then impacting the world. This is one of the most important stories of the COVID pandemic. We will be at the epicentre of this success story. read more
  • ELO, Oxford & AstraZeneca COVID-19 Vaccine: How to Solve a Global Problem? (Part II)

    How to Solve a Global Problem? (Part II) This series of four blog posts focus on the entrepreneurial story of how the University of Oxford invented a COVID-19 vaccine and entered into a partnership with AstraZeneca to distribute 3 billion doses globally. This year’s ELO Oxford Entrepreneurial Leaders Programme will include a case study of the development and roll-out of the Oxford AstraZeneca Vaccine and the lessons on innovation and entrepreneurship to be learned for global business leaders. The ELO Oxford cohort will get first-hand insights into how to go from idea to opportunity to then impacting the world. This is one of the most important stories of the COVID pandemic. We will be at the epicentre of this success story. read more
  • ELO, Oxford & AstraZeneca COVID-19 Vaccine: How to Go from Idea to Opportunity? (Part I)

    How To Go From Idea To Opportunity? (Part I) This series of four blog posts focus on the entrepreneurial story of how the University of Oxford invented a COVID-19 vaccine and entered into a partnership with AstraZeneca to distribute 3 billion doses globally. This year’s ELO Oxford Entrepreneurial Leaders Programme will include a case study of the development and roll-out of the Oxford AstraZeneca Vaccine and the lessons on innovation and entrepreneurship to be learned for global business leaders. The ELO Oxford cohort will get first-hand insights into how to go from idea to opportunity to then impacting the world. This is one of the most important stories of the COVID pandemic. We will be at the epicentre of this success story. read more
  • Glenn Cooke, CEO, Cooke Aquaculture: The Entrepreneurial Spirit (Part IV)

    Glenn Cooke is CEO of Cooke Aquaculture and The Cooke Family Group of Companies based in Blacks Harbour, New Brunswick. This interview was conducted by Rick Goossen, Chairman, ELO Group as part of the ELO Forum Toronto Online held on November 23, 2020. This is the fourth of a series of four blog posts. read more